Clinical Trial Update: Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the safety and tolerability of KH631 gene therapy in participants with neovascular age-related macular degeneration; study status is ac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• KH631

Snippet

Sponsor: Chengdu Origen Biotechnology Co., Ltd. | Conditions: Age-Related Macular Degeneration | Phase 1 | Status: ACTIVE_NOT_RECRUITING